Archives

OncoC4 announces first participant’s dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer’s disease

B ROCKVILLE, Md., April 9, 2026 /PRNewswire/ — OncoC4 Inc., a late clinical stage biopharmaceutical company, today announced first participant’s dosing following the clearance of the Investigational New Drug (IND) application…

Read MoreOncoC4 announces first participant’s dosing in Phase 1/2 clinical trial of ONC-841 for the treatment of Alzheimer’s disease

VSBLTY ANNOUNCES CONTRACT AWARD AND INITIAL DEPLOYMENT OF MULTI-SENSOR GOVERNED INTELLIGENCE PLATFORM FOR DEFENSE EARLY-WARNING, COUNTER DRONE, AND CRITICAL INFRASTRUCTURE PROTECTION

B $2.5 Million Initial Deployment Leverages VSBLTY’s Sovereign Intelligence Architecture for Multi-Domain Defense, Counter Drone Operations, and Critical Infrastructure Protection PHILADELPHIA, April 9, 2026 /PRNewswire/ — VSBLTY Groupe Technologies Corp.…

Read MoreVSBLTY ANNOUNCES CONTRACT AWARD AND INITIAL DEPLOYMENT OF MULTI-SENSOR GOVERNED INTELLIGENCE PLATFORM FOR DEFENSE EARLY-WARNING, COUNTER DRONE, AND CRITICAL INFRASTRUCTURE PROTECTION